Partial response was seen in 32.9% of children in the placebo group versus 40.6% in the IgG-AT1L group. The extensive immunoregulatory response while receiving only IgG-AT1, IgG-AT3, or placebo was found to be 56.2% in the IgG-AT1L group versus 53.1% in the IgG-AT1L-matched group. Blood Sample: IgG-AT1 (yellow), IgG-AT3 (green), and placebo.